mounjaro tirzepatide patent expiration us Republican Administration Maintains Exclusivity Stance in GLP-1 (Tirzepatide) Compounding Dispute Eli Lilly boss reports progress
Description
Typically, we find that patients taking FDA-approved GLP-1 agonists such as Ozempic and Wegovy will lose 10% of weight by 6 months and 15% within 1 year
Our team carefully evaluates patients to determine eligibility for tirzepatide therapy
When properly compounded with accurate potency, the active ingredient is identical
Months 6-12 and beyond (maintenance phase) Metabolic improvements plateau and stabilize
